RxDoctor Payments Data

Martita Marcano Perez, MD

Internal Medicine · Dundee, FLNPI 1275812901

Payments from drug & device makers

$327in general payments, 2019–2025

Across 18 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$53
  • AstraZeneca$49
  • Boston Scientific$42
  • Redhill Biopharma Inc.$33
  • Sanofi-aventis U.S. LLC$30
  • Novartis$29
  • plus $92 from 6 others

What the payments were for

  • Food & beverage$327100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$327 in reported general payments places this provider in the 45th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$3,087
Medicare patients
12
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$104,376
JardianceEmpagliflozin81$99,896
OzempicSemaglutide64$62,748
EntrestoSacubitril/Valsartan14$20,382
TrulicityDulaglutide20$18,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,786
MounjaroTirzepatide16$16,429
XareltoRivaroxaban18$14,056
Combivent RespimatIpratropium/Albuterol Sulfate11$5,458
SymbicortBudesonide/Formoterol Fumarate22$4,881
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$3,711
Albuterol Sulfate HfaAlbuterol Sulfate157$3,657
Novolin NInsulin Nph Human Isophane21$2,699
Levothyroxine Sodium174$2,283
Celecoxib45$2,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$16$105,35392 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin N$20$36,44549 claims
NovartisEntresto$29$20,38214 claims
GSKTrelegy Ellipta$53$17,78626 claims
AstraZenecaSymbicort$49$4,88122 claims
Sanofi-aventis U.S. LLCLantus$30$1,61211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Dundee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →